Humacyte Inc (HUMA) Price Prediction & ForecastHUMAHumacyte Inc

Alphio's HUMA stock price prediction model matches the current Humacyte Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $0.41 (+3.50%). The 1-week path is $0.40 (+1.00%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Humacyte Inc (HUMA) is currently trading at $0.3981, which is significantly below its 52-week high of $1.56, indicating a potential undervaluation. However, the stock has a low RSI of 37.916, suggesting it is nearing oversold conditions. The forward P/E ratio stands at 35.8423, which is relatively high, indicating that investors are expecting growth, but this also implies a risk if the company fails to meet these expectations. The recent FDA approvals for its products could drive future growth, but the company has reported substantial net losses, with a net income of -36802000 in Q2 2026. The main risk is the high volatility in its earnings and the speculative nature of its current valuation, as evidenced by the recent downgrade of revenue estimates by Benchmark from $6.6M to $4.9M for 2026. Therefore, while there are positive catalysts, the risks associated with the company's financial performance suggest a cautious approach for long-term investors.

Humacyte Inc (HUMA) last closed at $0.3955, losing -12.11%. These facts feed the 1-day and 1-week HUMA price prediction above.